Sarah Houdek, OD
Optometrist · Rapid City, SDNPI 1558974964
Payments from drug & device makers
What this record shows
Coopervision Inc. accounts for 71.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $1,719 and has fallen 96.2% since, to $65 in 2025.
Across 26 payments — averaging $84.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$2K
- Bausch & Lomb Americas Inc.$177
- Alcon$150
- Glaukos Corporation$147
- Amgen$72
- Johnson & Johnson Vision Care, Inc.$48
- plus $35 from 2 others
What the payments were for
- Travel & lodging$1,24757%
- Food & beverage$94343%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 10 | $1,562 |
| Bausch & Lomb Americas Inc. | 4 | $177 |
| Alcon | 5 | $150 |
| Glaukos Corporation | 1 | $147 |
| Amgen | 1 | $72 |
| Johnson & Johnson Vision Care, Inc. | 3 | $48 |
| Novartis | 1 | $20 |
| Tarsus Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MiSight Contact Lens$1,281
- MIEBO$125
- XIIDRA$125
How this compares
$2,190 in reported general payments places this provider in the 85th percentile of 206 optometrist providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 34 | $438 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Rapid City
- William HolecRapid City$2K
- Scott SchirberRapid City$2K
- Dawn WattenhoferRapid City$1K
- Sarah KuipersRapid City$1K
- Michael EllenderRapid City$1K
- Dwayne IceRapid City$1K
- Justin SchweitzerSioux Falls$753K
- Mitchel IbachSioux Falls$395K
- Jason SchmitSioux Falls$79K
- Darren DohmanAberdeen$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.